Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson,

Slides:



Advertisements
Similar presentations
Dinkar Kaw, M.D., Division of Nephrology
Advertisements

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
The PREVEND Study: Screening for micro-albuminuria
DIABETES AND THE KIDNEYS
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
(IRbesartan in MicroAlbuminuria, Type 2 Diabetic Nephropathy Trial)
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Early detection, prediction and potential treatment.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
The case of microalbuminuria prevention: the ROADMAP study Department for Clinical Pharmacology and Hypertension Charité – University Medicine Berlin,
Welch Center Uniting Medicine & Public Health Prevalence of Albuminuria, and its Relationship to Decreased GFR and Outcomes Josef Coresh, MD, PhD Director,
Managing Chronic Kidney Disease in the Elderly Veteran Ann M. O’Hare, MA MD Staff Physician, VAPSHCS Assistant Professor of Medicine University of Washington.
Lesley Stevens MD Tufts-New England Medical Center
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Microalbuminuria – pathogenesis and clinical implications.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Risk of Type 2 Diabetes and It’s Complications Along The Continuum of Fasting Plasma Glucose Gregory A. Nichols, PhD Collaborative Diabetes Education Conference.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Nephrology Core Curriculum Diabetic Nephropathy. Diabetic Nephropathy 35% of all the patients enrolled in the Medicare ESRD program –63% are type II $2.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint.
2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Hypertension Control and Progression of Renal Disease
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Optimum Re 2015 Charlotte A. Lee, M.D., FLMI, DBIM Proteinuria and Microalbuminuria.
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.
Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74 Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler,
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes Hermann Haller, M.D., Sadayoshi Ito, M.D., Ph.D., Joseph L. Izzo.Jr., M.D.,
Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
The Significance of Albuminuria
Section 4: Managing progression of CKD
ACCORD Microvascular Outcomes
Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy  Kantima Phisitkul, MD, Khaled Hegazy, MD, Temduang.
Chapter 1: CKD in the General Population
Estimated GFR in Diabetes
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure  Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu,
So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.
Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.
The percentage of subjects with de novo development of renal function impairment (GFR
Recent studies of ACE inhibition in renal disease
Management of hypertension in patients with chronic kidney disease
Chapter 1: CKD in the General Population
Update on Diabetic Nephropathy: Core Curriculum 2018
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes  Robert W. Schrier, Raymond.
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis  Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,
Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz 
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease  Johannes F.E. Mann, Qi-Long.
CKD in Aboriginal Australians
Cumulative incidences of events, according to glucose-control strategy
Update on Diabetic Nephropathy: Core Curriculum 2018
Proteinuria and hypertensive nephrosclerosis in African Americans
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Volume 63, Pages S13-S16 (February 2003)
Friends, social networks, and progressive chronic kidney disease
Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.
Presentation transcript:

Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson, MD, PhD NIDDK, Phoenix

Population  Pima Indians from the Gila River Indian Community in Arizona  Biennial examinations since 1965 of all community members ≥5 years old  Medical history/physical examination –Height, weight, blood pressure –Blood and urine tests –Retinal examinations and photographs –ECG –Oral Glucose Tolerance Test  Registries –ESRD –Mortality

Definitions Measure of Albuminuria Collection: Daytime untimed “spot” urine specimens Analyte: Urinary Albumin to Creatinine Ratio (ACR; in mg/g) Analytical methods: Albumin – immunonephelometry (Dade Behring, Inc.); Creatinine – modified Jaffe reaction (Envoy 500) Thresholds:<30 mg/g; normoalbuminuria (NA) mg/g; microalbuminuria (MA) ≥300 mg/g; macroalbuminuria Measure of Proteinuria Collection: Daytime untimed “spot” urine specimens Analyte: Urinary Protein to Creatinine Ratio (PCR; in g/g) Analytical methods: Protein – Shevky-Stafford; Creatinine – modified Jaffe reaction (Envoy 500) Thresholds:≥0.5 g/g (or ≥1.0 g/g in some studies)

Age-Sex-Adjusted Death Rates in Pima Indians ≥45 Years Old Diabetes 37: , 1988 Age-sex-duration adjusted death rate ratio 3.5 (95% CI, )

Prevalence of Elevated Albuminuria Diabetologia 32: , 1989

Incidence of Proteinuria by Level of Albuminuria Baseline Participants (N) – diabetic Pima Indians ≥15 years old439 Participants with urine ACR <30 mg/g (N) ≥30 mg/g (N) Study End Incidence rate ratio (MA/NA) of proteinuria (PCR ≥0.5g/g) [95%CI] 8.5 [ ] Arch Intern Med 151: , 1991 Figure. Age-sex-adjusted incidence of proteinuria in diabetic Pima Indians by albuminuria category.

Age-Sex-Adjusted Incidence of SCr ≥2.0 mg/dl by Duration of Diabetes and Presence of Proteinuria Kidney Int 35: , 1989 Age-sex-duration adjusted incidence rate ratio 42 (95% CI, 24-75)

Cumulative Incidence of ESRD by Duration of Proteinuria Duration of Proteinuria (years) Percent Diabetologia 36: , 1993 Whites with type 1 Pimas with type 2

Mean (±SE) Change in GFR According to Albuminuria at Baseline N Engl J Med 335: , 1996

Sequential Measures of Albuminuria 1 st ACR measurement (ACR -1 ; prior to baseline) Participants (N) – diabetic Pima Indians ≥15 years old983 (270 with MA) Urine ACR [median, 25 th and 75 th percentiles] 21 [11-67] 2 nd ACR measurement within 6 years (ACR 0 ; baseline) Participants (N)983 Urine ACR [median, 25 th and 75 th percentiles] 27 [13-121] Early change (Remission to NA <30 mg/g) (N)65 (24%) Study End Incidence of ESRD for each doubling of ACR 0 [95%CI] 1.7 [ ] Death rate from natural mortality for each doubling of ACR 0 [95%CI] 1.2 [ ] Am J Kidney Dis 51: , 2008

Changes in ACR Categories Between Two ACR Measurements Taken Within a 6-year Period ACR 0 <30 mg/g mg/g mg/g≥ 3000 mg/gTotal <30 mg/g 460 (76.5%) 129 (21.5%)11 (1.8%)1 (0.2%)601 ACR mg/g65 (24.1%) 155 (57.4%) 45 (16.7%)5 (1.8%) mg/g2 (2.2%)12 (13.0%) 46 (50.0%) 32 (34.8%)92 ≥ 3000 mg/g01 (5.0%)2 (10.0%) 17 (85.0%) 20 Total Am J Kidney Dis 51: , 2008

Incidence Rate Ratio for Diabetic ESRD (N=89 cases) Relative to Persistently Normal ACR Am J Kidney Dis 51: , 2008 ACR 0 NormalMicroMacro Normal13.1 ( )24.9 ( ) ACR -1 Micro1.9 ( )4.5 ( )20.5 ( ) Macro03.8 ( )15.4 ( )

Incidence of Diabetic ESRD Kidney Int 70: , 2006

Summary  MA occurs frequently in type 2 diabetes  MA predicts development of overt nephropathy  MA frequently regresses to normoalbuminuria  Low current ACR is associated with a good prognosis regardless of earlier values  Proteinuria strongly predicts progression to renal insufficiency, ESRD, and death  Distribution of albuminuria is changing over time